Published in BMC Res Notes on June 07, 2010
Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood (2014) 1.60
Acquired hemophilia A: a frequently overlooked autoimmune hemorrhagic disorder. J Immunol Res (2014) 0.84
Acquired hemophilia A: emerging treatment options. J Blood Med (2015) 0.83
Management of bleeding in acquired haemophilia A with recombinant activated factor VII: does one size fit all? A report of four cases. Blood Transfus (2014) 0.78
Efficacy of Corticosteroids Alone in the Eradication of Factor VIII Inhibitor in an Old Female with Idiopathic Acquired Haemophilia A: Description of a Case. Case Rep Rheumatol (2012) 0.75
Treatment of bleeding in acquired hemophilia A with the proper administration of recombinant activated factor VII: single-center study of 7 cases. Int J Gen Med (2016) 0.75
Successful Long Term Eradication of Factor VIII Inhibitor in Patients with Acquired Haemophilia A in Saudi Arabia. Mediterr J Hematol Infect Dis (2012) 0.75
Acquired Hemophilia A with a Rare Presentation of Acute Subdural Hematoma. Case Rep Neurol Med (2015) 0.75
Use of recombinant activated factor VII for acute bleeding episodes in acquired hemophilia: final analysis from the Hemostasis and Thrombosis Research Society Registry acquired hemophilia study. Blood Coagul Fibrinolysis (2016) 0.75
Acquired haemophilia A: the importance of early recognition in cases of spontaneous bleeding in the elderly. BMJ Case Rep (2014) 0.75
Acquired hemophilia A in a patient treated by Ginkgo-dipyridamolum. Clin Case Rep (2017) 0.75
Acquired inhibitors: a special case of bleeding in older adults. Curr Gerontol Geriatr Res (2012) 0.75
Influence of factor VIII level and its inhibitor titer on the therapeutic response to corticosteroids alone in the management of acquired hemophilia: A retrospective single-center study. Medicine (Baltimore) (2016) 0.75
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 11.84
Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. Chest (2006) 4.77
A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost (1981) 4.39
Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood (2006) 3.71
International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica (2009) 3.63
Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol (2003) 2.91
Acquired factor VIII inhibitors. Blood (2008) 2.67
Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor. Ann Intern Med (1989) 2.27
Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol (2000) 2.14
Rituximab in the treatment of acquired factor VIII inhibitors. Blood (2002) 1.99
The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol (2006) 1.90
A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood (2006) 1.78
Acquired haemophilia and its management. Br J Haematol (1995) 1.69
DDAVP in acquired hemophilia A: case report and review of the literature. Am J Hematol (1993) 1.69
Successful treatment of acquired hemophilia with oral immunosuppressive therapy. Ann Intern Med (1997) 1.66
A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost (1993) 1.50
A population based, unselected, consecutive cohort of patients with acquired haemophilia A. Br J Haematol (2004) 1.49
Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood (2004) 1.49
Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood (1993) 1.46
The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost (1997) 1.45
Acquired haemophilia. Baillieres Clin Haematol (1998) 1.41
Treatment of acquired hemophilia A. J Thromb Haemost (2007) 1.30
Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept. Blood (2004) 1.27
Treatment of acquired haemophilia with factor eight inhibitor bypassing activity. Haemophilia (2004) 1.23
Rituximab in the treatment of adult acquired hemophilia A: a systematic review. Crit Rev Oncol Hematol (2007) 1.17
Acquired hemophilia due to factor VIII inhibitors in 34 patients. Am J Med (1998) 1.17
Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med (1987) 1.17
Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal. Haemophilia (2007) 1.15
Acquired factor VIII inhibitors in non-haemophilic patients: clinical experience of 15 cases. Haemophilia (2004) 1.15
Detection of factor VIII inhibitors with the partial thromboplastin time. Blood (1977) 0.91
1-Deamino-8-D-arginine vasopressin in the treatment of non-haemophilic patients with acquired factor VIII inhibitor. Haemostasis (1990) 0.87
Acquired factor VIII inhibitor treated with cyclophosphamide, vincristine, and prednisone. Am J Hematol (2002) 0.87
Acquired factor VIII inhibitors in nonhemophilic patients. Ann Hematol (1997) 0.85
Immunoadsorption may provide a cost-effective approach to management of patients with inhibitors to FVIII. Transfusion (2003) 0.84
Rituximab in the treatment of acquired factor VIII inhibitors. Thromb Haemost (2006) 0.84
Human factor VIII for bleeding in patients with inhibitors. Vox Sang (1999) 0.82
Desmopressin therapy in patients with acquired factor VIII inhibitors. Lancet (1988) 0.82
The effect of 1-deamino 8 D-arginine vasopressin (DDAVP) in a nonhaemophilic patient with an acquired type II factor VIII inhibitor. Br J Haematol (1985) 0.81
Production of thromboxane and prostaglandins in human blood in the presence of thromboxane synthase inhibitors: a comparison of RIA and GC/MS determinations. Blood Coagul Fibrinolysis (1991) 0.80
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.65
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet (2008) 3.74
International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica (2009) 3.63
Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation (2007) 3.17
D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med (2015) 2.63
Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med (2002) 1.95
Diagnosis and treatment of disseminated intravascular coagulation: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res (2011) 1.78
Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood (2012) 1.74
End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood (2002) 1.73
Microvascular free flap failure caused by unrecognized hypercoagulability. Plast Reconstr Surg (2009) 1.66
Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood (2012) 1.65
Successful in vivo propagation of factor IX-producing hepatocytes in mice: potential for cell-based therapy in haemophilia B. Thromb Haemost (2008) 1.49
Diagnostic performance and therapeutic consequence of thromboelastometry activated by kaolin versus a panel of specific reagents. Anesthesiology (2011) 1.48
Monoclonal gammopathy in extranodal marginal zone lymphoma (ENMZL) correlates with advanced disease and bone marrow involvement. Am J Hematol (2004) 1.47
A new drug delivery system for intravenous coronary thrombolysis with thrombus targeting and stealth activity recoverable by ultrasound. J Am Coll Cardiol (2012) 1.43
Whole blood coagulation in children with thrombocytopenia and the response to platelet replacement, recombinant factor VIIa, and a potent factor VIIa analogue. Br J Haematol (2008) 1.41
Mutant macaque factor IX T262A: a tool for hemophilia B gene therapy studies in macaques. Thromb Res (2010) 1.41
Novel FV mutation (W1920R, FVNara) associated with serious deep vein thrombosis and more potent APC resistance relative to FVLeiden. Blood (2014) 1.40
Multidisciplinary approach to the challenge of hemostasis. Anesth Analg (2009) 1.37
Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost (2006) 1.35
High homocysteine and thrombosis without connective tissue disorders are associated with a novel class of cystathionine beta-synthase (CBS) mutations. Hum Mutat (2002) 1.29
Reference gene selection for real-time RT-PCR in regenerating mouse livers. Biochem Biophys Res Commun (2008) 1.20
Femoral head blood flow reduction and hypercoagulability under 24 h megadose steroid treatment in pigs. J Orthop Res (2004) 1.19
Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives. Blood Coagul Fibrinolysis (2004) 1.17
A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med (2012) 1.14
Antibody to marinobufagenin lowers blood pressure in pregnant rats on a high NaCl intake. J Hypertens (2005) 1.12
Antithrombin, heparin, and heparan sulfate. Crit Care Med (2002) 1.09
Fibrinogen estimates are influenced by methods of measurement and hemodilution with colloid plasma expanders. Transfusion (2010) 1.08
Vasorelaxant action of 17 -estradiol in rat uterine arteries: role of nitric oxide synthases and estrogen receptors. Am J Physiol Heart Circ Physiol (2007) 1.07
Acute venous disease: venous thrombosis and venous trauma. J Vasc Surg (2007) 1.06
Drug-induced anti-factor VIII antibodies: a systematic review. Med Sci Monit (2007) 1.06
Intrauterine growth restriction in rats is associated with hypertension and renal dysfunction in adulthood. Am J Physiol Endocrinol Metab (2002) 1.04
Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis (2003) 1.00
Mechanisms of plasmin-catalyzed inactivation of factor VIII: a crucial role for proteolytic cleavage at Arg336 responsible for plasmin-catalyzed factor VIII inactivation. J Biol Chem (2006) 0.97
Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model. Blood (2010) 0.97
Diagnosis, laboratory aspects and management of acquired hemophilia A. Intern Emerg Med (2010) 0.96
Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situations. Thromb Haemost (2008) 0.93
Endothelial function and biochemical vascular markers in first-degree relatives of type 2 diabetic patients: the effect of exercise training. Metabolism (2006) 0.92
The pivotal role of thrombin in cancer biology and tumorigenesis. Semin Thromb Hemost (2009) 0.92
ADAMTS13 safeguards the myocardium in a mouse model of acute myocardial infarction. Thromb Haemost (2012) 0.91
Intrinsic pathway of blood coagulation contributes to thrombogenicity of atherosclerotic plaque. Blood (2002) 0.91
Plasmin-induced procoagulant effects in the blood coagulation: a crucial role of coagulation factors V and VIII. Blood Coagul Fibrinolysis (2010) 0.91
Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). Br J Haematol (2012) 0.91
Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study. Thromb Haemost (2012) 0.90
Fibrinogen concentrate--a potential universal hemostatic agent. Expert Opin Biol Ther (2009) 0.89
Early atheroma in primary and secondary antiphospholipid syndrome: an intrinsic finding. Semin Arthritis Rheum (2007) 0.88
Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER). Haematologica (2013) 0.88
Regulation of coagulation factors during liver regeneration in mice: mechanism of factor VIII elevation in plasma. Thromb Res (2011) 0.87
A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate. Thromb Haemost (2006) 0.87
Flow-based measurements of von Willebrand factor (VWF) function: binding to collagen and platelet adhesion under physiological shear rate. Thromb Res (2009) 0.87
Isolated Richter's transformation of the brain. J Neurooncol (2007) 0.86
Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A. Br J Haematol (2007) 0.85
Severe aplastic anemia associated with eosinophilic fasciitis: report of 4 cases and review of the literature. Medicine (Baltimore) (2013) 0.85
A case of infantile Alexander disease diagnosed by magnetic resonance imaging and genetic analysis. Brain Dev (2007) 0.85
Insights into atherosclerosis therapy in antiphospholipid syndrome. Autoimmun Rev (2007) 0.85
Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still's disease. Joint Bone Spine (2013) 0.84
Modulation of body fluids and angiotensin II receptors in a rat model of intra-uterine growth restriction. J Physiol (2004) 0.84
Cautions and caveats to the treatment of acquired hemophilia A. Haematologica (2009) 0.84
Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting. Thromb Haemost (2008) 0.84
Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006-2010): based on registry data from the Japanese Society of Pediatric Hematology. Int J Hematol (2013) 0.84
The factor VIIIa C2 domain (residues 2228-2240) interacts with the factor IXa Gla domain in the factor Xase complex. J Biol Chem (2008) 0.84
Consumption of clotting factors in severe haemophilia patients undergoing prophylaxis and on-demand treatment in Italy. Transfus Med (2011) 0.84
Reversal of low-molecular-weight heparin-induced bleeding in patients with pre-existing hypercoagulable states with human recombinant activated factor VII concentrate. Am J Hematol (2006) 0.84
Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation (2005) 0.83
Immunosuppressive treatment for acquired haemophilia: current practice and future directions in Germany, Austria and Switzerland. Ann Hematol (2008) 0.83
Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial. Blood Coagul Fibrinolysis (2008) 0.83
Recombinant, activated factor VII for surgery in factor VII deficiency: a prospective evaluation - the surgical STER. Br J Haematol (2010) 0.83
Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost (2012) 0.83
Short communication: decreasing soluble CD30 and increasing IFN-gamma plasma levels are indicators of effective highly active antiretroviral therapy. AIDS Res Hum Retroviruses (2007) 0.82
Different factor VIII neutralizing effects on anti-factor VIII inhibitor antibodies associated with epitope specificity and von Willebrand factor. Br J Haematol (2013) 0.82
Characterization of anti-factor VIII antibody in a patient with acquired hemophilia A. Blood Res (2013) 0.82
A successful reconstruction using a frozen autograft and a pedicled latissimus dorsi flap after a S12345B shoulder girdle resection in a patient with osteosarcoma. J Reconstr Microsurg (2011) 0.81
Arterial stiffness and stroke in sickle cell disease. Stroke (2011) 0.81
Platelet infusion supports recombinant factor VIIa in a patient with severe haemophilia A and inhibitor--clinical outcome and laboratory observations. Thromb Haemost (2010) 0.81
A critical role for thrombin in platelet aggregation under high shear stress. Thromb Res (2004) 0.81
Suitable reference genes for the analysis of direct hyperplasia in mice. Biochem Biophys Res Commun (2008) 0.81
Identification and characterisation of mutations associated with von Willebrand disease in a Turkish patient cohort. Thromb Haemost (2013) 0.81
Therapeutic effects of hepatocyte transplantation on hemophilia B. Transplantation (2008) 0.81
Localization of the low-density lipoprotein receptor-related protein regions involved in binding to the A2 domain of coagulation factor VIII. Thromb Haemost (2007) 0.81
The binding sites for the very low density lipoprotein receptor and low-density lipoprotein receptor-related protein are shared within coagulation factor VIII. Blood Coagul Fibrinolysis (2008) 0.81
Lupus anticoagulant hypoprothrombinemia syndrome in Bence-Jones protein κ-type multiple myeloma patient with phosphatidylserine-dependent antiprothrombin antibody. Ann Hematol (2012) 0.81
Human factor VIII inhibitor alloantibodies with a C2 epitope inhibit factor Xa-catalyzed factor VIII activation: a new anti-factor VIII inhibitory mechanism. Thromb Haemost (2002) 0.80
Correlations between global clotting function tests, duration of operation, and postoperative chest tube drainage in pediatric cardiac surgery. Paediatr Anaesth (2011) 0.80
High-sodium intake prevents pregnancy-induced decrease of blood pressure in the rat. Am J Physiol Heart Circ Physiol (2003) 0.80
A novel mechanism of factor VIII protection by von Willebrand factor from activated protein C-catalyzed inactivation. Blood (2002) 0.80
Plasma cysteine and glutathione are independent markers of postmethionine load endothelial dysfunction. Clin Biochem (2006) 0.80
Use of recombinant factor VIIa during orthotopic liver transplantation. Liver Transpl (2006) 0.80
Protein C deficiency as the major cause of thrombophilias in childhood. Pediatr Int (2013) 0.80
A putative inhibitory mechanism in the tenase complex responsible for loss of coagulation function in acquired haemophilia A patients with anti-C2 autoantibodies. Thromb Haemost (2012) 0.80
Identification of a protein S-interactive site within the A2 domain of the factor VIII heavy chain. Thromb Haemost (2009) 0.80
Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia. J Immunol (2008) 0.80
Expression of coagulation factors from murine induced pluripotent stem cell-derived liver cells. Blood Coagul Fibrinolysis (2011) 0.80